Condition: Follicular Lymphoma · Sponsor: Fondazione Italiana Linfomi - ETS
This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.
This description comes directly from the study's public registry record.
Uffici Studi FIL · +390131033153 · startup@filinf.it
Uffici Studi FIL · +390599769913 · gestionestudi@filinf.it
Always discuss trial participation with your own doctor first.
| Royal Adelaide Hospital | Adelaide, Australia | Recruiting |
| Liverpool Hospital | Liverpool, Australia | Recruiting |
| St. Vincent Hospital Melbourne | Melbourne, Australia | Recruiting |
| Princess Alexandra Hospital | Woolloongabba, Australia | Recruiting |
| Fondazione del Piemonte per l'Oncologia - IRCCS, Ematologia | Candiolo, Torino, Italy | Recruiting |
| AOU SS. Antonio e Biagio e Cesare Arrigo, SCDU Ematologia | Alessandria, Italy | Recruiting |
| AOU Ospedali Riuniti, Clinica di Ematologia | Ancona, Italy | Recruiting |
| Azienda Ospedaliera S.Giuseppe Moscati, S.C. Ematologia e Trapianto emopoietico | Avellino, Italy | Recruiting |
| IRCCS Istituto Tumori Giovanni Paolo II, U.O.C Ematologia | Bari, Italy | Recruiting |
| Policlinico S.Orsola-Malpighi, Istituto di Ematologia "Seragnoli" | Bologna, Italy | Recruiting |
| ASST Spedali Civili di Brescia, Ematologia | Brescia, Italy | Recruiting |
| Azienda Ospedaliera Universitaria Policlinico - S. Marco, UOC di Ematologia | Catania, Italy | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06492837